Low-dose multicomponent medication modulates humoral and cellular immune response in an ex-vivo study on children subjected to adenoid surgery

Sara Carlotta Tagliacarne, Chiara Valsecchi, Marco Benazzo, Michele Nichelatti, Alessia Marseglia, Giorgio Ciprandi, Sergio Bernasconi

Research output: Contribution to journalArticlepeer-review

Abstract

Respiratory infections, mainly in children, are a demanding challenge for physicians. Commonly, a relative immune-defect sustains their recurrence. At present, there is no standardized treatment for their prevention acting on the immune system. Citomix is a low-dose multicomponent medication largely used in this issue. The current study evaluated its ex vivo effect on adenoidal mononuclear cells recovered from children operated for adenoid hypertrophy. B cell phenotype, and IFN-γ, IL-6, IL-10, IgG, IgA, IgM in culture supernatants were evaluated. Citomix was able to significantly increase the expression of B memory cells, IFN-γ, IL-6, IgA and IgM, and significantly decrease IL-10 and IgG. The current outcomes could be consistent with a strategy deputed to improve the early immune response to pathogens. In conclusion, the present ex vivo study suggests that Citomix might be a promising medication in preventing and early treating respiratory infections.

Original languageEnglish
Pages (from-to)95-101
Number of pages7
JournalImmunology Letters
Volume203
DOIs
Publication statusPublished - Nov 1 2018

Keywords

  • Adenoidal cells
  • B memory cells
  • Children
  • IFN-γ
  • IgA
  • IgG
  • IgM
  • IL-10
  • IL-6
  • Low-dose multicomponent medication
  • Respiratory infections
  • SKA (sequential kinetic activation)

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Fingerprint Dive into the research topics of 'Low-dose multicomponent medication modulates humoral and cellular immune response in an ex-vivo study on children subjected to adenoid surgery'. Together they form a unique fingerprint.

Cite this